Feb 5, 2025 · ONAPGO TM: A Newly-Approved Medication for OFF Periods in Parkinson’s. Breaking News! The first subcutaneous (under the skin) apomorphine infusion, now called ONAPGO TM, was approved by the Food and Drug Administration (FDA) on February 4, 2025.Apomorphine is a dopamine agonist whose effects have a rapid onset.

Feb 4, 2025 · The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) for the continuous treatment of motor fluctuations in adults with advanced Parkinson’s disease, making it the first subcutaneous, or under-the-skin, apomorphine infusion device approved for this indication.

ONAPGO (apomorphine HCL) injection, for sc infusion is a continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease patients.

ONAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. ONAPGO is indicated for subcutaneous use by infusion only [see Warnings & Precautions (5.1)].

5 days ago · Onapgo is the first and only wearable subcutaneous apomorphine infusion device that provides continuous treatment during the waking day, offering patients more consistent control of motor fluctuations. The product is expected to be available in …

For many, continuous treatment options like Onapgo can help to make days with Parkinson’s more predictable.” About the Phase 3 Study During the Phase 3 study, Onapgo significantly reduced the amount of daily OFF time at 12 weeks from baseline (p=0.0114), with Onapgo-treated patients (n=53) experiencing a 2.6-hour reduction compared to ...

6 days ago · The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine...

Feb 4, 2025 · Nearly 4 and a half years since its original submission, the FDA has approved Supernus Pharmaceuticals’ investigational agent SPN-830 (Onapgo) as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson disease (PD).

5 days ago · THURSDAY, Feb. 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced Parkinson disease, according to a news release from Supernus Pharmaceuticals.

Feb 4, 2025 · The U.S. Food and Drug Administration (FDA) on February 4, 2025, approved Onapgo (apomorphine hydrochloride), a new Parkinson’s therapy for people with progressing Parkinson’s disease who experience significant “off” time (when symptoms are not controlled) or motor fluctuations, which are ups and downs in symptom control throughout the day. . Onapgo uses a continuous, under-the-skin ...